用于支持药械注册的现实世界研究统计学思考

doi:10.19803/j.1672-8629.2022.01.06

中国药物警戒 ›› 2022, Vol. 19 ›› Issue (1): 27-31.
DOI: 10.19803/j.1672-8629.2022.01.06

• 真实世界数据支持药械监测与评价(一）专栏 • 上一篇下一篇

用于支持药械注册的现实世界研究统计学思考

黄丽红¹, 陈峰²

¹复旦大学附属中山医院生物统计室,上海 200032;
²南京医科大学公共卫生学院生物统计学系,江苏南京 211166

收稿日期:2021-09-30 出版日期:2022-01-15 发布日期:2022-01-20
作者简介:黄丽红,女,博士,青年研究员·硕导,临床研究中统计理论方法与规范化。
基金资助:
国家自然科学基金青年科学基金项目（81903407）

Statistical considerations for real world studies supporting new drug registrations

HUANG Lihong¹, CHEN Feng²

¹Department of Biostatistics, Zhongshan Hospital, Fudan University, Shanghai 200032, China;
²Department of Biostatistics, School of Public Health, Nanjing Medical University, Nanjing Jiangsu 211166, China

Received:2021-09-30 Online:2022-01-15 Published:2022-01-20

摘要/Abstract

摘要： 目的探讨现实世界研究（RWS）获得现实世界证据（RWE）的统计学问题。方法对现实世界数据（RWD）,RWS的因果推断方法及RWE的评价方式进行总结,分析现存问题。结果获得可靠的RWE用于支持药械监管是RWS的重要目标,适当的RWD通用标准是进行数据质量评价的前提,规范化的数据治理和完善的数据质量评价体系是规范开展RWS的基础,因果推断方法的规范化实施是获得可靠RWE的质量保障,临床上可解释的、有创新性价值的结论是RWE的首要前提,在具体实践中需要客观的RWE判定标准,RWS结果的可验证性是不可忽视的RWE的重要特征。结论单一的临床研究往往无法满足因果关系的判定标准,需要多个研究从不同角度加以验证,RWS与随机对照试验（RCT）互为验证的因果推断研发模式值得推广。

关键词: 现实世界研究, 现实世界数据, 现实世界证据, 因果推断, 数据质量

Abstract: Objective To review statistics-related problems in the process of obtaining real world evidence (RWE) from real world research (RWS). Methods In regard to real world data (RWD), causal inference methods for RWS and approaches to RWE evaluation were reviewed while the existing problems were analyzed and discussed. Results Obtaining reliable RWE that could be used to support regulatory decisions about medical products was an important goal of RWS. An appropriate standard for RWD data was a prerequisite for quality evaluation of the data. A standardized process of data governance and a perfect system for data quality evaluation underlay high-quality RWS. Standardized implementation of causal inference analytical methods could ensure the quality of RWE. Clinically explicable and innovative conclusions were critical to RWE. Objectivecriteria for evaluation of RWE were also needed in practice. The verifiability of results of RWS was the most important feature of RWE. Conclusion A single clinical trial is often unable to meet the criteria for determining causality. Instead, multiple studies are required to verify causality from different perspectives. Therefore, the combination of randomized controlled trials (RCT) and RWS is a good approach during drug development.

Key words: real world study, real world data, real world evidence, causal inference, data quality

中图分类号:

R911

黄丽红, 陈峰. 用于支持药械注册的现实世界研究统计学思考[J]. 中国药物警戒, 2022, 19(1): 27-31.

HUANG Lihong, CHEN Feng. Statistical considerations for real world studies supporting new drug registrations[J]. Chinese Journal of Pharmacovigilance, 2022, 19(1): 27-31.

参考文献

[1] BLACK N.Why we need observational studies to evaluate the effectiveness of health care[J]. BMJ, 1996, 312(7040): 1215-1218.
[2] LI M, SHI JP, YU HH.Relationship between the“Real World” research, randomized controlled trial and number of one randomized controlled trial in clinical therapeutic study[J]. Chinese Journal of Epidemiology(中华流行病学杂志), 2012, 33(3): 342-345.
[3] Food and Drug Administration. Use of real world evidence to support regulatory decision marking for medical devices[EB/OL]. (2017-08-31)[2021-08-14]. https://www.fda.gov/media/99447/download.
[4] National Medical Products Administration. Guidelines for drug development and review supported by real-world evidence (trial document)[EB/OL]. (2020-01-03)[2021-08-14]. https://www.nmpa.gov.cn/xxgk/ggtg/qtggtg/20200107151901190.html.
[5] National Medical Products Administration. Real-world data guidelines for generating real-world evidence (Trial document)[EB/OL]. (2021-04-15)[2021-08-14] https://www.cde.org.cn/main/news/viewInfoCommon/2a1c437ed54e7b838a7e86f4ac21c539.
[6] BOOTH CM, KARIM S, MACKILLOP WJ.Real-world data: towards achieving the achievable in cancer care[J]. Nat Rev Clin Oncol, 2019, 16(5): 312-325.
[7] CHEN DF, LIU H.Methods and applications of medical big data mining(医学大数据挖掘方法与应用)[M]. Beijing: Peking University Medical Press, 2020.
[8] MAKADY A, HAM RT, DE BOER A, et al.Policies for use of real-world data in health technology assessment (HTA): a comparative study of six HTA agencies[J]. Value Health, 2017, 20(4): 520-532.
[9] KAHN MG, CALLAHAN TJ, BARNARD J, et al.A harmonized data quality assessment terminology and framework for the secondary use of electronic health record data[J]. EGEMS (Wash DC), 2016, 4(1): 1244.
[10] Food and Drug Administration. Standardization and querying of data quality metrics and characteristics for electronic health data-data quality metrics system final report [EB/OL]. (2019-12-31)
[ 2021-08-14]. https://dataquality.healthdatacollaboration.net/.
[11] PEARL J, GLYMOUR M, JEWELL NP.Causal inference in statistics: a primer[M]. John Wiley, 2016.
[12] HERNÁN MA, ROBINS JM. Causal inference: what if[M]. Boca Raton: Chapman & Hall/CRC, 2020.
[13] QIU JP.Practical measurement methods for causal inference(因果推断实用计量的方法)[M]. Shanghai: Shanghai University of Finance and Economics Press, 2020.
[14] HUANG LH, WEI YY, CHEN F.Confounder adjustment in observational comparative effectiveness researches II: statistical adjustment approaches for unmeasured confounders[J]. Chinese Journal of Epidemiology(中华流行病学杂志), 2019, 40(11): 1450-1455.
[15] STERNE JA, HERNÁN MA, REEVES BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions[J]. BMJ, 2016, 355: i4919.
[16] SHEN HB.Epidemiology (Vol. 3)[流行病学(第3卷)][M]. Beijing: People's Medical Publishing House, 2014.
[17] TANG JL, YANG ZY.Observation versus experiment, efficacy versus effectiveness[J]. Chinese Journal of Epidemiology(中华流行病学杂志), 2014, 35(3): 221-222.

用于支持药械注册的现实世界研究统计学思考

Statistical considerations for real world studies supporting new drug registrations

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 5

编辑推荐

Metrics

[1]	梁馨元, 莫毅, 冯硕, 杨焕, 莫兆军. 疫苗临床试验电子数据信息采集系统的研发与安全性监测[J]. 中国药物警戒, 2019, 16(12): 711-715.
[2]	万帮喜, 余丽娜, 徐菊萍. 基于ICH E2B（R3）指南理解个例安全性报告数据质量[J]. 中国药物警戒, 2019, 16(10): 597-601.
[3]	韩贺东,郭威,叶小飞,许金芳,郭晓晶,朱田田,史文涛,王蒙,侯永芳,贺佳. 目标最大似然估计在药品安全性主动监测中的应用[J]. 中国药物警戒, 2017, 14(6): 341-345.
[4]	李庆娜,陆芳,高蕊,. 临床研究不良事件报告标准及报告质量探讨[J]. 中国药物警戒, 2015, 12(5): 302-304.
[5]	刘建平, 邢建民. 循证的药品不良反应评价方法[J]. 中国药物警戒, 2010, 7(1): 12-15.